Tag Archives: drugs

FDA Issues Guidance on Classification of Products as Drugs and Devices & Additional Product Classification Issues

FDA Issues Guidance on Classification of Products as Drugs and Devices & Additional Product Classification Issues

Full Text Here

FDA regularly receives requests from medical product developers concerning the classification of their products. We believe that efficient, effective regulation of such products is facilitated by providing guidance on issues frequently raised in relation to such requests. Certain issues have arisen often relating to whether a product should be classified as a drug or a device. Accordingly, this guidance focuses particularly on when a product may be classified as a drug or a device. This guidance also addresses additional issues relating to product classification, including how to obtain a formal classification determination from FDA for a medical product and the status of prior Agency determinations concerning product classification.
This guidance is organized into three substantive sections.
Section II offers guidance on the process to obtain a formal determination of whether a product is classified as a drug, device, biological product, or combination product.
Section III provides some general concepts for making classification determinations and addresses specific issues arise in determining whether products should be classified as drugs or devices

Section IV of this document provides an overview of the status of the current intercenter jurisdictional agreements, classifications that have been made by regulation, and classifications the Agency has made for a product that does not fall within the scope of a regulation, for example, by granting a marketing authorization or in responding to a request for designation.
The Agency recommends that manufacturers contact the Office of Combination Products (OCP) to confirm the classification of any products they may wish to market if the appropriate classification appears unclear for any reason. Section V provides contact information for OCP.

For Assistance with Development of Drug Device Combinations Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

FDA Publish Guidance on Open Public Hearings at FDA Meetings

FDA Publish Guidance on Open Public Hearings at FDA Meetings.

Full Text Here

The Food and Drug Administration’s (FDA’s) advisory committees play an essential role in FDA’s activities to protect and promote public health through the regulation of human and animal drugs, biological products, medical devices, foods, and tobacco products. FDA’s advisory committees provide independent expert advice and recommendations to the Agency on scientific, technical, and policy matters related to FDA-regulated products. Advisory committees enhance FDA’s ability to protect and promote public health by ensuring FDA has access to such advice through the public hearing process as provided in existing laws and regulations. Although advisory committees provide recommendations to FDA, FDA makes the final decisions on any matters considered by an advisory committee. General procedures for FDA advisory committees are described at 21 CFR Part 14.

FDA encourages participation from all public stakeholders in its decision-making processes. Every advisory committee meeting includes an open public hearing (OPH) session, during which interested persons may present relevant information or views orally or in writing (21 CFR 14.25(a)). FDA’s regulation, 21 CFR 14.29, requires that a minimum of 60 minutes per meeting be dedicated to an OPH session for oral presentations, unless public participation does not last that long. For meetings that extend more than 1 day and/or meetings with multiple topics, the OPH session can be divided into multiple parts. If there is an overwhelming interest by the advisory committee in a specific topic, then the committee chair2 may extend the OPH session.
The time and location of the meeting and the OPH session is published in the Federal Register (21 CFR 14.20) at least 15 days before a meeting.
This guidance is intended to answer questions about how the public may participate at an OPH session. This includes, but is not limited to, general members of the public; individuals or spokespersons from the regulated industry (except the sponsor whose product is under review); consumer advocacy groups; and professional organizations, societies, or associations.

For Assistance Presenting Evidence to the FDA click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Drug Regulators, FDA, Publish Guidance For Industry on Content of a Compleate Submission for the Evaluation of Proprietary Names

Drug Regulators, FDA, Publish Guidance For Industry on Content of a Complete Submission for the Evaluation of Proprietary Names.

Full Text Here

This guidance describes for industry the information that FDA uses to evaluate proposed proprietary names for certain drugs, including biological products, under the traditional review process within the time frames set out in Prescription Drug User Fee Act (PDUFA IV) performance goals. The review clock for the performance review goals begins when the Agency receives a complete submission2 (see sections II. Background and III. PDUFA IV Goal Dates).
Accurate identification of medications is critical to preventing medication errors and potential harm to the public. This guidance is intended to assist industry in the submission of a complete package of information that FDA will use in the assessment of:
1. the safety aspects of a proposed proprietary name, to reduce medication errors, and
2. the promotional implications of a proposed proprietary name, to ensure compliance with other requirements for labeling and promotion using our traditional review methods.
This guidance applies to proprietary name submissions for the following types of products:
• prescription drug products, including biologics, that are the subject of an investigational new drug application (IND), a new drug application (NDA), an abbreviated new drug application (ANDA), or a biologics license application (BLA)
• nonprescription drug products that are the subject of an IND, NDA, or ANDA
This guidance does not describe the methods used for evaluation of proposed proprietary names using the traditional review process, nor does the guidance describe the information needed by FDA to evaluate proposed proprietary names under the voluntary 2-year pilot program being conducted by CDER and CBER. That information can be found in the FDA concept paper entitled “PDUFA Pilot Project Proprietary Name Review,” dated September 2008.

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulattions, rules and initiatives each month, and summarise them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 Drug Regulators, FDA, Publish Guidance For Industry on Content of a Compleate Submission for the Evaluation of Proprietary Names

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes Drug Regulators, FDA, Publish Guidance For Industry on Content of a Compleate Submission for the Evaluation of Proprietary Names

Drug Regulators, FDA- CDER, Publish Guidance on the Assessment of Abuse Potential of Drugs

Drug Regulators, FDA- CDER, Publish Guidance on the Assessment of Abuse Potential of Drugs.

Full Text Here

This guidance is intended to assist sponsors who are developing drug products with the potential for abuse that may need to be scheduled under the Controlled Substances Act (21 U.S.C. 811(b), 811(c)). Examples of products that are addressed in this guidance include new molecular entities and new dosage forms of drug substances already controlled under the Controlled Substances Act (21 U.S.C. 812(c)). Drugs with abuse potential generally include drugs that affect the central nervous system, drugs that are chemically or pharmacologically similar to other drugs with known abuse potential, and drugs that produce psychoactive effects such as sedation, euphoria, or mood change.2

Specifically, the guidance discusses the following:

• The definition of abuse potential

• Information on submitting an abuse potential assessment, including a proposal for scheduling

• A description of what constitutes an adequate abuse potential assessment

• Information for sponsors performing an assessment, including (1) the design and conduct of appropriate studies and investigations and (2) general administrative recommendations for submitting a proposal for scheduling

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulattions, rules and initiatives each month, and summarise them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 Drug Regulators, FDA  CDER, Publish Guidance on the Assessment of Abuse Potential of Drugs

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes Drug Regulators, FDA  CDER, Publish Guidance on the Assessment of Abuse Potential of Drugs